(Q43038360)

English

Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy

scientific article published in July 2002

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Alan S. Perelson

7

object named as

Alan S Perelson

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Leor S Weinberger

3

object named as

Leor Weinberger

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

Hugo R Rosen

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Stephanie Wolf

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Minjun Chung

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

David R Gretch

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 July 2002

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

124-130

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Viral hepatitis in the liver transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapy for hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical Pharmacokinetics of Interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Functional role of type I and type II interferons in antiviral defense

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C in African Americans: summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900114-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0168-8278(02)00114-9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43038360&oldid=1978297270"